Insmed (NASDAQ:INSM) reported quarterly losses of $(1.54) per share which missed the analyst consensus estimate of $(1.12) by 37.38 percent. This is a 16.67 percent decrease over losses of $(1.32) per share from the same period last year. The company reported quarterly sales of $263.843 million which beat the analyst consensus estimate of $221.898 million by 18.90 percent. This is a 152.62 percent increase over sales of $104.442 million the same period last year.